Search | Clinical Trials Finder

Conditions: Peptic Ulcer
Interventions: Endoscopic Translumenal Omental Patch; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Gastric Ulcer
Interventions: PA32540, EC Aspirin 325; Drug
Lead sponsor: POZEN; Industry
Eligibility: 55 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Erosive Esophagitis
Interventions: Omeprazole/sodium bicarbonate; Drug
Lead sponsor: Yvonne Romero; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions: XmAb13676; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 10
States / cities: La Jolla, California • Jacksonville, Florida • Atlanta, Georgia + 7 more

Conditions: Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions: Cessation of Acid Suppressing Medications; Other
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions: PN 200 tablets (500 mg naproxen and 20 mg omeprazole), Naproxen 500 mg tablets (PN 200 minus omeprazole); Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Pompano Beach, Florida

Conditions: Upper Gastrointestinal Bleeding
Interventions: Clinician notification, Clinician Notification with Nurse Facilitation, Clinician Notification / Patient Activation, Clinician Notification with Nurse Facilitation / Patient Activation; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions: Not listed
Lead sponsor: Epic Research & Diagnostics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 353 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Attack, Cardiac Arrest, Congestive Heart Failure, Atrial Fibrillation, Angina, Deep Vein Thrombosis, Pulmonary Embolism, Respiratory Arrest, Respiratory Failure, Pneumonia, Gastrointestinal Bleed, Stomach Ulcer, Delirium, Stroke, Nerve Injury, Surgical Wound Infection
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 73,952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Helicobacter Pylori Infection, Gastric Ulcer, Nausea, Abdominal Pain, Weight Loss, Stomach Ulcer, Loss of Appetite, Bloating
Interventions: Post-Therapy; Other
Lead sponsor: DiaSorin Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Mission Hills, California • Great Neck, New York • Mentor, Ohio + 1 more

Conditions: Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC), Hepatocellular Carcinoma, Ulcerative Colitis, Esophageal Cancer, Squamous Cell Carcinoma, Gastric/GEJ, Cervical Cancer, Gastro-Esophageal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions: nivolumab, pembrolizumab; Drug
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions: Famotidine, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Minute to 12 Months
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Achalasia, Gastric Fistula, Weight Gain After Primary Weight Loss Surgery, Marginal Ulcer, Stenoses, Gastric Nec
Interventions: Endoscopic Intervention; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2031
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Gastrinoma, Zollinger Ellison Syndrome
Interventions: Pantoprazole, Omeprazole; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1983 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Upper GI Bleeding, Bleeds Gastric, Bleed Ulcer, Hemorrhage Gastric, Hemorrhage; Ulcer
Interventions: Metoclopramide 10mg, Saline; Drug
Lead sponsor: Mercy Health System; Network
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rockford, Illinois

Conditions: Gastric Ulcer
Interventions: Esomeprazole Sodium; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 5
States / cities: Newark, Delaware • Shreveport, Louisiana • Hershey, Pennsylvania + 2 more

Conditions: Osteoarthritis
Interventions: LT-NS001, Naprosyn®; Drug
Lead sponsor: Logical Therapeutics; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 65
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 51 more

Conditions: Gastric Ulcer, Duodenal Ulcer
Interventions: Esomeprazole 40 mg, Esomeprazole 20 mg, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 55
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 52 more

Conditions: Achalasia, Esophageal, GERD (Gastroesophageal Reflux Disease)
Interventions: Conventional POEM, Sling Fiber-Preserving POEM; Procedure
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Orange, California

Conditions: Esophageal Adenocarcinoma, Barrett's Esophagus, Reflux Esophagitis
Interventions: Chlorhexidine gluconate; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroendocrine Tumors
Interventions: Capecitabine, Temozolomide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Marginal Ulcer
Interventions: Omeprazole 40 milligrams; Drug
Lead sponsor: Stephen Firkins; Other
Eligibility: Not listed
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Peptic Ulcer Hemorrhage
Interventions: Pantoprazole; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 6
States / cities: Los Angeles, California • San Diego, California • Cincinnati, Ohio + 3 more

Conditions: Indigestion
Interventions: Esomeprazole, Placebo; Drug · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Kansas City, Kansas

Search by objective public record fields.

Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus

A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial

Prognostic Indicators as Provided by the EPIC ClearView

Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes Surveys

Helicobacter Pylori Sample Collection Protocol Post Therapy Subjects

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

Outcome Analysis of POEM and Endoluminal Therapies

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid

Metoclopramide in Upper Gastrointestinal Bleed

An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium

Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

Sling-Fiber Preservation POEM vs. Conventional POEM for Reducing Post-POEM GERD

Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome

Capecitabine and Temozolomide for Neuroendocrine Cancers

OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients